- Home
- EVV vs XERS Comparison
EVV vs XERS Comparison
Compare EVV & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- XERS
- Stock Information
- Founded
- EVV 2003
- XERS 2005
- Country
- EVV United States
- XERS United States
- Employees
- EVV N/A
- XERS N/A
- Industry
- EVV Finance/Investors Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- XERS Health Care
- Exchange
- EVV Nasdaq
- XERS Nasdaq
- Market Cap
- EVV 1.2B
- XERS 1.3B
- IPO Year
- EVV N/A
- XERS 2018
- Fundamental
- Price
- EVV $10.17
- XERS $8.33
- Analyst Decision
- EVV
- XERS Strong Buy
- Analyst Count
- EVV 0
- XERS 7
- Target Price
- EVV N/A
- XERS $8.00
- AVG Volume (30 Days)
- EVV 323.7K
- XERS 2.1M
- Earning Date
- EVV 01-01-0001
- XERS 11-07-2025
- Dividend Yield
- EVV 9.66%
- XERS N/A
- EPS Growth
- EVV N/A
- XERS N/A
- EPS
- EVV N/A
- XERS N/A
- Revenue
- EVV N/A
- XERS $246,025,000.00
- Revenue This Year
- EVV N/A
- XERS $43.89
- Revenue Next Year
- EVV N/A
- XERS $20.40
- P/E Ratio
- EVV N/A
- XERS N/A
- Revenue Growth
- EVV N/A
- XERS 35.62
- 52 Week Low
- EVV $8.52
- XERS $2.73
- 52 Week High
- EVV $10.07
- XERS $8.51
- Technical
- Relative Strength Index (RSI)
- EVV 48.79
- XERS 61.63
- Support Level
- EVV $10.07
- XERS $7.88
- Resistance Level
- EVV $10.23
- XERS $8.51
- Average True Range (ATR)
- EVV 0.08
- XERS 0.37
- MACD
- EVV -0.01
- XERS -0.01
- Stochastic Oscillator
- EVV 52.63
- XERS 83.05
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).